secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001437749-25-004224
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals adjusts exec compensation; CEO salary $565k, options at $1.80
--------------------------------------------------------------------------------

- Dr. Bhat base salary to $565k; CFO Prabhu $330k; VP Bhat $340k, effective retroactive Jan 1, 2025.
- 2024 cash bonuses: Dr. Bhat $157,500; Mr. Prabhu $79,950; Ms. Bhat $77,500.
- 2025 bonus targets: 50% of base (CEO), 41% (CFO), 32% (VP), subject to Compensation Committee criteria.
- Option grants at $1.80 strike: CEO 519k shares, CFO 194.25k, VP 181.5k; ~42% vested immediately, rest monthly through Dec 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925004224/0001437749-25-004224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925004224/rvph20250214_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-004224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer